InfuSystem Holdings Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole mounted and ambulatory infusion pumps; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. InfuSystem Holdings Inc. was founded in 2005 and is headquartered in Madison Heights, Michigan.
Industry, Sector and Symbol
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Phone+1-248-2911210
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees237
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable
InfuSystem (NYSEAMERICAN:INFU) Frequently Asked Questions
What is InfuSystem's stock symbol?
InfuSystem trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "INFU."
How will InfuSystem's stock buyback program work?
InfuSystem announced that its board has initiated a stock buyback plan on Tuesday, March 13th 2018, which allows the company to buyback 1,000,000 shares, according to EventVestor. This buyback authorization allows the company to buy shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company's board believes its shares are undervalued.
How were InfuSystem's earnings last quarter?
InfuSystem Holdings Inc (NYSEAMERICAN:INFU) issued its earnings results on Wednesday, November, 13th. The medical instruments supplier reported $0.05 earnings per share for the quarter. The medical instruments supplier had revenue of $21.49 million for the quarter. View InfuSystem's Earnings History.
When is InfuSystem's next earnings date?
Has InfuSystem been receiving favorable news coverage?
News headlines about INFU stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. InfuSystem earned a news sentiment score of -2.6 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for InfuSystem.
Are investors shorting InfuSystem?
InfuSystem saw a decline in short interest in the month of November. As of November 15th, there was short interest totalling 19,900 shares, a decline of 32.1% from the October 31st total of 29,300 shares. Based on an average daily trading volume, of 38,700 shares, the short-interest ratio is presently 0.5 days. Currently, 0.1% of the shares of the stock are short sold. View InfuSystem's Current Options Chain.
Who are some of InfuSystem's key competitors?
Some companies that are related to InfuSystem include Advanced Medical Solutions Group (AMS), Clover (CLV), CRH Medical (CRH), CRH Medical (CRHM), CRH Medical (CRHM), Bovie Medical (BVX), Tristel (TSTL), SDI (SDI), Milestone Scientific (MLSS), Impression Healthcare (IHL), TransEnterix (TRXC), Retractable Technologies (RVP), IsoRay (ISR), TSO3 (TOS) and Daxor (DXR).
What other stocks do shareholders of InfuSystem own?
Who are InfuSystem's key executives?
InfuSystem's management team includes the folowing people:
- Mr. Richard A. DiIorio, Pres, CEO & Director (Age 44)
- Mr. Gregory Schulte, Exec. VP & CFO (Age 52)
- Mr. Thomas Mark Ruiz, Sr. VP of Sales & Marketing
- Mr. John Haggerty, Sr. VP of Biomedical Services & Logistics
- Ms. Jean Pfeiffer, Sr. VP of Strategic Initiatives
Who are InfuSystem's major shareholders?
InfuSystem's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Gabelli Funds LLC (1.82%). Company insiders that own InfuSystem stock include Awm Investment Company, Inc, Christopher R Sansone, David C Dreyer, Gregg Owen Lehman, Meridian Ohc Partners, Lp, Richard Dilorio, Ronald H Jr Peele, Scott Shuda and Terry L Armstrong. View Institutional Ownership Trends for InfuSystem.
Which institutional investors are buying InfuSystem stock?
INFU stock was acquired by a variety of institutional investors in the last quarter, including Gabelli Funds LLC. Company insiders that have bought InfuSystem stock in the last two years include Awm Investment Company, Inc, Christopher R Sansone, Gregg Owen Lehman, Meridian Ohc Partners, Lp, Richard Dilorio, Ronald H Jr Peele, Scott Shuda and Terry L Armstrong. View Insider Buying and Selling for InfuSystem.
How do I buy shares of InfuSystem?
Shares of INFU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is InfuSystem's stock price today?
One share of INFU stock can currently be purchased for approximately $7.73.
How big of a company is InfuSystem?
What is InfuSystem's official website?
How can I contact InfuSystem?
InfuSystem's mailing address is 31700 Research Park Dr, MADISON HEIGHTS, MI 48071-4627, United States. The medical instruments supplier can be reached via phone at +1-248-2911210.
MarketBeat Community Rating for InfuSystem (NYSEAMERICAN INFU)
MarketBeat's community ratings are surveys of what our community members think about InfuSystem and other stocks. Vote "Outperform" if you believe INFU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INFU will underperform the S&P 500 over the long term. You may vote once every thirty days.
